

November 9, 2018

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir,

Sub: Analyst / Investor call

Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we inform you that an analyst / investor call on the Unaudited Financial Results of the Company for the second quarter and half year ended 30th September, 2018 is scheduled on 13th November 2018 at 8:30 AM.

Please find attached the dial-in details of the call.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED



B. Adi Reddy
Company Secretary



9th November 2018, Hyderabad, India

Aurobindo Pharma Limited Q2 FY18-19 earnings call is scheduled on 13th November 2018 at 8:30 hrs

The dial-in details to participate in the call is as under. You may also pre-register in the call through the link mentioned below.

Please dial the below number at least 5 minutes prior to the conference schedule to ensure that you are connected to your call in time.

Primary Number: +91 22 6280 1292 / +91 22 7115 8193

The number listed above are universally accessible from all networks and all countries.

Local Access Number: +91-7045671221
Available all over India

Toll Free Number: USA: 1866 746 2133
UK: 0808 101 1573
Singapore: 800 101 2045
Hong Kong: 800 964 448

Pre-register Link (URL) <http://services.choruscall.in/diamondpass/registration?confirmationNumber=8047377>

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com) (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, Anti-Allergies and Anti-Diabetics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 150 countries.

For further information, please contact:

Krishna Kiran
Investor Relations,
Phone: 040-66725401 / 66725000
Mobile: +91 98486 67906
Email: ir@aurobindo.com

